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The two winners of the 2012 Nobel Prize in Physiology or Medicine share more than just this honor; they are
both also fearless adventurers, in science and beyond.This year’s Nobel Prize in Physiology or
Medicine was awarded to John Gurdon
and Shinya Yamanaka for solving key
problems of biology. Their work provided
fundamental insights into how an egg
gives rise to a complex organism consist-
ing of many different cell types and has
transformed our understanding of nuclear
reprogramming, of embryonic develop-
ment, and of cellular differentiation. These
are issues that have a long history and the
reader is referred to a comprehensive
review by Graf (2011) on cellular plasticity
and a summary of current issues of the re-
programming field by Yamanaka (2012).
Here I will give a personal view on how
the discoveries of Gurdon and Yamanaka
have shaped our understanding of basic
mechanisms of development and how
stem cells will revolutionize the way we
investigate human disease and establish
novel treatment strategies.
For the longest time, biologists tried to
unveil the process of how a fertilized egg
creates an organism that consists of
hundreds of specialized cell types that
are all expressing different sets of genes.
Development of an embryo to the adult
was seen as a unidirectional process,
and the differentiated state of specialized
cells like skin or liver cells as fixed irre-
versibly. How specific combinations of
proteins could be synthesized and main-
tained in different cell types needed an
explanation. Two competing hypotheses
were envisioned. August Weissmann
and Wilhelm Roux proposed in the late
19th century that cells become different
by selective loss of genetic material that
was not needed and retain only those
genes essential for the function of the
respective tissue, as has been seen in
some animal species. The second hypo-
thesis posed that differentiated cells may
retain all genes but regulate their expres-744 Cell Stem Cell 11, December 7, 2012 ª2sion in a tissue-specific manner. Gurdon
and Yamanaka’s seminal work resolved
these questions. We now know that the
genome is conserved during develop-
ment, and that the differentiated state is
reversible. Moreover, in the process
Gurdon and Yamanaka shed light on the
nature of stem cells and pluripotency.
John Gurdon: Is Genetic
Information Lost in Development?
Though interested in science fromayoung
age, Gurdon’s entrance into biological
science was highly discouraged by his
biology teacher, who said of Gurdon,
‘‘While having ideas to becomea scientist,
this is quite ridiculous as judged from his
present showing: he can’t even learn
simple biological facts and would have
no chance of doing thework of a specialist
and it would be a waste of time, both on
his part and of those who have to teach
him.’’ A prophecy that now makes us
smile!
A stringent prediction of the Weiss-
mann-Roux concept was that nuclei of
differentiated cells would lose the ability
to generate a new organism. In contrast,
if all genes were retained and the process
of differentiation was reversible, a somatic
nucleus would maintain the potential to
form a new organism when transplanted
into the egg. In 1952 Briggs and King
performed the first successful nuclear
transfer (NT) experiments in the frog
Rana pipiens. When nuclei from cleavage
embryos were used as donors they ob-
tained swimming tadpoles, but later stage
nuclei had lost this potential and formed
only abnormal clones. They concluded
that differentiation involves irreversible
nuclear changes and the production of
animals by nuclear cloning from somatic
donors would be impossible, and that
conclusion became generally accepted012 Elsevier Inc.in the field until John Gurdon made his
crucial discovery.
Working as a student in the laboratory
of embryologist Michail Fischberg,
Gurdon decided to test the Weissman-
Roux hypothesis in Xenopus rather
than Rana eggs. For practical reasons
this was an excellent choice because
Xenopus, in contrast to Rana, can
produce eggs all year round. His early
experiments challenged the conclusions
of Briggs and King: nuclei derived from
intestinal cells of tadpoles, when injected
into the egg, were able to direct develop-
ment to mature adults (Gurdon, 1960;
Gurdon and Uehlinger, 1966). This
seminal discovery made a persuasive
case that development does not in fact
involve irreversible genetic changes. It
took 30 years for Keith Campbell and Ian
Wilmut to repeat this experiment in
mammals by generating Dolly, the first
cloned mammal derived by transfer of an
adult somatic nucleus into an enucleated
sheep egg (Wilmut et al., 1997). To prove
that nuclei of mature adult cells rather
than tissue stem cells retained totipo-
tency, Gurdon used expression of tissue-
specific markers in the donor cells.
However, because cloning was so ineffi-
cient the question of whether nuclei of
mature adult cells were indeed totipotent
was only settled later when it was shown
that all cells of cloned mice harbored
the appropriate IgG or T cell receptor
gene rearrangements when derived from
mature B or T donor cells (Hochedlinger
and Jaenisch, 2002).
The molecular mechanism of nuclear
reprogramming by the egg has been of
great interest to biologists and has largely
remained unsolved even today. Because
of the egg’s small size, biochemical
analyses of the reprogramming process
in the mammalian egg are difficult.
JohnGurdon as amountaineer in the 1990s during theHaute Route (a
strenuous 7 day ski trek crossing high mountains from Chamonix in
France to Zermatt in Switzerland) (top), and on Mt. Harvard, which is
among the highest peaks in the ‘‘collegiate’’ range in central
Colorado (bottom). Photos courtesy of J. Gurdon.
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Xenopus oocyte, in contrast
to the mammalian system,
would provide a better oppor-
tunity. He used the Xenopus
egg as a living test tube
and showed, for example,
that nuclei from differentiated
cells, when transferred into
the oocyte, silenced genes
expressed in the somatic
donor cell and activated
oocyte-specific genes (De
Robertis and Gurdon, 1977).
The important conclusion
was entirely consistent with
differential gene expres-
sion driving development
because it showed that
genes, which had become
inactive during cell differenti-
ation, can be reactivated
by normal components of
the oocyte cytoplasm in the
absence of cell division.
These experiments were per-
formed in the 1970s at a time
before today’s routine molec-
ular tests such as Southern
analysis, PCR, or genomic
analyses had been invented,
yet the conclusions have
stood the test of time. In
more recent years Gurdon
introducedmammalian nuclei
into the Xenopus oocyte and,using modern experimental tools, has
embarked on defining molecular events
of early stages in nuclear reprogramming.
Given the different developmental strate-
gies of frog and mammal it will be impor-
tant though challenging to confirm that
conclusions from these interspecies
experiments accurately reflect what
happens to the mammalian nucleus
when transferred into themammalian egg.
When I first read about NT, I was deeply
impressed by the elegance and the bold-
ness of Gurdon’s experiments and later
by the clarity of his lectures. It may come
as no surprise that he is as passionate
and fearless outside of science. He used
to bicycle 20 km to work, still plays tennis
and competitive squash, and has made
adventurous treks to the high mountains.
For example, in search of Meconopsis,
a beautiful poppy plant that only blooms
in the monsoon season at an altitude of
14,000 feet, he embarked on long andtreacherous treks into the high mountains
of India. In the 1990s he trekked into the
mountains of New Guinea, completed
the Haute Route (a demanding 7 day ski
trek though the high French and Swiss
Alps), and climbed Mt. Harvard, one of
the highest peaks in the Rockies (see
photos). Ten years ago he decided it
was time to learn parachute jumping, an
idea provoked by one of his students
who had become an expert in this activity.
His first jump was 1 day before his daugh-
ter’s wedding and 1 week after a lethal
accident had occurred due to the failure
of a chute to open, all circumstances
that, as he told me, caused his wife
some concern. A water skiing accident
necessitating hip replacement has not
dampened his resolve to plan a serious
hiking trip into the Himalayas to see rho-
dodendrons in bloom. Today, at 79 years
of age, Gurdon retains the skills to inject
nuclei and comes every day to the labCell Stem Cell 11, December 7,to do his experiments. He
occupies a small office that
also houses his microscope.
Because the University does
not allow the placement of
scientific instruments in an
office, he has declared his
office to be his laboratory,
which just happens to also
contain his desk.
Gurdon’s classic NT exper-
iments established for the
first time that nuclei of differ-
entiated cells remain totipo-
tent and retain the potential
to produce a new organism.
His experiments did not
address whether differenti-
ated cells can be reprog-
rammed back to an undiffer-
entiated pluripotent state.
The answer to this question
would come from the work
of Shinya Yamanaka.
Shinya Yamanaka: How
Does the Egg Reset the
Genome?
In the late 1990s, two break-
throughs stirred the scientific
community as well as the
public: the generation of
Dolly, the first mammal
cloned from an adult donor
cell, and the derivation of
human embryonic stem cells(ESCs) by Jamie Thomson (Thomson
et al., 1998). Together these discoveries
raised the possibility of customized
therapy for human degenerative ailments
such as Parkinson’s or heart disease
with what was dubbed ‘‘therapeutic
cloning.’’ The idea was that patient-
specific pluripotent ESCs could be ob-
tained by NT of a skin cell nucleus into
a human egg, which then would be differ-
entiated to the cell type that was defective
in the patient. The differentiated cells
would be transplanted back into the
patient to cure the underlying disease
without the complication of immune rejec-
tion.While therapeutic cloningwas shown
to work in animals, its application to
humans faced serious technical, prac-
tical, and ethical obstacles that subse-
quent work has still not been able to over-
come (Hyun, 2011). Importantly, it was
inconceivable that sufficient numbers of
human eggs could ever be obtained for2012 ª2012 Elsevier Inc. 745
Shinya Yamanaka as a student with lab members at Osaka City University Graduate School
in 1992 (left) and as rugby player while a medical student at Kobe University in 1985 (right).
Photos courtesy of S. Yamanaka.
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moral objections were raised to using
human eggs and cloned embryos for
research and therapy. Thus, the only
option was to understand how the egg
accomplishes the resetting of the somatic
genome to a pluripotent state, which
would circumvent the need to use human
eggs in the process. The mechanism of
nuclear reprogramming during cloning
became a hot research aim that capti-
vated many laboratories. It is here where
Yamanaka made his groundbreaking
discovery.
During his high school years, Yama-
naka practiced judo and earned a black
belt. He enrolled in medical school, where
his focus was on playing rugby (see
photos) at the expense, as he told me, of
attending classes. Serious practice of
judo and rugby is tough on the body,
and he suffered numerous bone fractures
necessitating intimate and painful expo-
sure to medicine as patient. These experi-
ences convinced him to pursue a medical
career and become an orthopedic
surgeon. However, medical school was
not to his liking: he had to follow text-
books and supervisors closely. Neverthe-
less, he finished medical school and got
his M.D. degree, only to realize that
surgery and the manual dexterity involved
were not his calling. Instead, he decided
to study for a Ph.D. in pharmacology.
Excited by the isolation of human ESCs
and their potential for medicine, he set
out to define the molecular determinants
of the pluripotent state.
The mammalian egg is about 1,0003
larger than a somatic cell and harbors746 Cell Stem Cell 11, December 7, 2012 ª2numerous gene products that are crucial
for the early development of the embryo
and, it was assumed, for reprogramming
the somatic nucleus after NT. It was
a daunting task to identify which of the
many proteins present in the egg might
be responsible for resetting the somatic
cell genome back into an embryonic
state. In the early 2000s several laborato-
ries had defined the key factors respon-
sible for the maintenance of ESCs with
the transcription factors Oct4, Sox2, and
Nanog being at the top of an autoregula-
tory gene expression circuitry required
for pluripotency and self-renewal. While
this discovery suggested to many that
expression of these genes in somatic cells
would be essential to induce reprogram-
ming, they surely were not deemed suffi-
cient on their own—the process had to
be far more complex.
Yamanaka dropped a bombshell on the
field at the 2006 ISSCR meeting in
Toronto when he announced that only
four transcription factors were needed to
reprogram a somatic nucleus to pluripo-
tency. Kazutoshi Takahashi, a student in
his lab, had performed an experiment
that seemed unlikely to succeed. From
a list of genes expressed in ESCs, but
not in somatic cells, they had selected
24 candidates, which were packaged
into retroviral vectors and cotransduced
into fibroblasts that carried a neo resis-
tance marker in the Fbx15 gene. Fbx15
is downstream of Oct4 and is not
expressed in fibroblasts but is active in
pluripotent ESCs. If any combination of
the 24 candidate genes could induce
reprogramming, the rare reprogrammed012 Elsevier Inc.cell would become neomycin resistant
and thus could be isolated (Takahashi
and Yamanaka, 2006). From the point of
view of a retrovirologist, as I am by
training, this scheme seemed bold and
unlikely to work because cotransduction
of multiple genes into a single cell
would be exceedingly unlikely. However,
because of the strong selection, they
were able to isolate reprogrammed
cells designated as ‘‘induced Pluripotent
Stem’’ cells (iPSCs) by transduction of
only four genes: Oct4 and Sox2 and the
oncogenes c-Myc and Klf4. While the
importance of Oct4 and Sox2 was more
or less predictable, the choice of c-Myc
and Klf4 was, in my judgment, brilliant.
As it turned out later, the two oncogenes
are not required for reprogramming, but
they made the process more efficient,
and made detection of rare reprog-
rammed cells possible.
Yamanaka’s talk at the ISSCR meeting
was met with disbelief and skepticism
by most: impossible that reprogramming
was that simple! Knowing Yamanaka
and his rigorous scientific standards,
I was convinced immediately. But the
iPSCs reported in the initial landmark
publication were not equivalent to ESCs:
they had not activated the endogenous
pluripotency circuitry and were unable
to generate chimeras. A year later, using
a modified approach, three groups,
including Yamanaka’s, reported the
generation of iPSCs that were indistin-
guishable from ESCs. Confirmation from
three independent labs convinced the
community and led to an explosion of
the reprogramming field. Five months
after that, several groups reported re-
programming of human cells, attesting
to the robustness of the Yamanaka
approach. The prospect of using human
iPSCs for disease research and for cell-
based therapy has electrified the scien-
tific community and beyond, generating





Nuclear reprogramming by NT versus re-
programming initiated by transcription
factors raised an interesting question:
how similar or different are the molecular
mechanisms that reset the genome? Has
direct reprogramming by transcription
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achieves epigenetic resetting of the
somatic nucleus after NT?
It had been established early on that
pluripotency factors are reactivated
within one or two cell divisions after NT
into the mouse egg or without DNA repli-
cation after transfer of somatic nuclei
into the Xenopus oocyte (see, for
example, De Robertis and Gurdon, 1977,
and later work from the Gurdon lab). In
contrast, direct reprogramming is ineffi-
cient and iPSCs appear only after multiple
cell divisions. Thus, it was postulated that
themolecular mechanism in NT and direct
reprogramming would be very different:
reprogramming by NT might be a ‘‘deter-
ministic’’ process resulting in rapid hierar-
chical activation of pluripotency genes, in
contrast to iPSC formation that requires
multiple ‘‘stochastic’’ or probabilistic
epigenetic events that only accumulate
after many cycles of DNA replication.
However, there is still much to learn
about the mechanisms that underlie re-
programming, and recent studies have
suggested that direct reprogramming
takes place in distinct stages and may
well have a more deterministic compo-
nent than previously assumed.
The concept that ectopic expression of
transcription factors can reprogram
somatic cells to pluripotency was soon
extended and applied to converting cells
from one somatic lineage to another,
a process called ‘‘transdifferentiation.’’
The idea that key transcription factors
can change the differentiation state of
a cell had been established in principle
some time before (as described by Graf,
2011). For example, conversion of fibro-
blasts into muscle cells by transfection
of MyoD by Harold Weintraub or Pu-1-
mediated conversion of lymphoid cellsinto macrophages by Thomas Graf were
among the first demonstrations that a
single transcription factor could convert
one cell type into another. Although the
early experiments achieved conversion
of cells within a given lineage, more recent
studies have applied the Yamanaka
approach to transdifferentiate cells of
one germ layer to that of another, such
as fibroblasts to neurons or liver cells.
The approach has even been extended
to the in vivo conversion of exocrine to
endocrine pancreas cells (for details of
these and the early experiments, see
Graf, 2011). Successful transdifferentia-
tion was inspired by Yamanaka’s dis-
covery of inducing reprogramming with
several transcription factors and shows
that the iPSC approach has significance
beyond just the conversion of somatic to
pluripotent cells.
What Lies Ahead?
The most immediate application of iPSC
technology is the study of human disease:
iPSCs derived from a given patient
carry all genetic determinants that have
contributed to the disease and thus repre-
sent an unparalleled system to study the
etiology of diseases in the Petri dish.
They also offer screening for potential
drugs and might be used for cell-based
therapy at some point in the future.
Although technical issues pertaining to
the significance of genetic and epigenetic
differences between ESCs and iPSCs and
a number of safety concerns still need to
be resolved, and robust protocols for the
differentiation of iPSCs into functional
cells need to be developed (for detailed
discussion see Yamanaka, 2012), it is
a safe prediction that this approach will
change the way we will investigate and
treat diseases.Cell Stem Cell 11,The direct reprogramming of somatic
cells with only a few transcription factors
has fundamental medical implications
and arguably represents the most impor-
tant finding in the stem cell field since
Gurdon’s demonstration of reprogram-
ming by nuclear transplantation. It took
Gurdon 50 years after his original
discovery and Yamanaka a mere 6 years
to be recognized by the highest scientific
honor. This difference, I believe, reflects
the breathtaking progress in the stem
cell field following the first report on
iPSCs, and the likely unprecedented
impact that iPSC technology will have on
medicine in the years to come.
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